Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,687
  • Shares Outstanding, K 64,114
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,430 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 0.17
  • Price/Sales 86.91
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 406.96% (+39.25%)
  • Historical Volatility 103.32%
  • IV Percentile 90%
  • IV Rank 49.50%
  • IV High 703.98% on 01/24/25
  • IV Low 115.86% on 07/14/25
  • Expected Move (DTE 20) 1.3600 (74.73%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 2,777
  • Volume Avg (30-Day) 1,877
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 43,464
  • Open Int (30-Day) 34,044
  • Expected Range 0.4600 to 3.1800

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.27
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +79.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6800 +8.33%
on 12/22/25
2.5375 -28.28%
on 12/17/25
+0.1400 (+8.33%)
since 11/26/25
3-Month
1.0400 +75.00%
on 10/06/25
2.5375 -28.28%
on 12/17/25
+0.8499 (+87.61%)
since 09/26/25
52-Week
0.7900 +130.38%
on 08/28/25
3.3900 -46.31%
on 08/26/25
+0.1200 (+7.06%)
since 12/26/24

Most Recent Stories

More News
Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
GDP in Canadian Spotlight Next Week

Monday U.S. Featured Earnings Bridgeline Digital Inc (NASDAQ: BLIN) (Q4) EPS ...

BLIN : 0.9301 (-2.73%)
OTLK : 1.8200 (-0.55%)
LMNR : 12.82 (-0.62%)
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
Micron Dominates Barchart's Top 100 with Killer Volume—Your Buy Signal?

In Monday’s trading, Micron Technology jumped 14 spots in Barchart’s Top 100 Stocks to Buy, into 36th position. Of the top 100, Micron’s price volume was the highest at 6.53 million, nearly four...

IREN : 40.30 (-4.00%)
OTLK : 1.8200 (-0.55%)
NVDA : 190.53 (+1.02%)
MU : 284.79 (-0.66%)
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update on Type A Meeting with FDA

ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Requests Type A Meeting with FDA

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment...

OTLK : 1.8200 (-0.55%)
OTLKW : 0.03 (-1.96%)
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...

OTLK : 1.8200 (-0.55%)
KNSA : 42.00 (-1.15%)
CRMD : 12.53 (+2.79%)
PHAR : 17.80 (-1.60%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 2.0833
2nd Resistance Point 2.0167
1st Resistance Point 1.9183
Last Price 1.8200
1st Support Level 1.7533
2nd Support Level 1.6867
3rd Support Level 1.5883

See More

52-Week High 3.3900
Fibonacci 61.8% 2.3968
Fibonacci 50% 2.0900
Last Price 1.8200
Fibonacci 38.2% 1.7832
52-Week Low 0.7900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar